AGL 6.90 Increased By ▲ 0.45 (6.98%)
ANL 9.77 Increased By ▲ 0.07 (0.72%)
AVN 76.82 Decreased By ▼ -0.78 (-1.01%)
BOP 5.49 Increased By ▲ 0.06 (1.1%)
CNERGY 5.05 Increased By ▲ 0.08 (1.61%)
EFERT 79.83 Increased By ▲ 2.58 (3.34%)
EPCL 57.48 Increased By ▲ 1.99 (3.59%)
FCCL 15.30 Decreased By ▼ -0.06 (-0.39%)
FFL 6.48 No Change ▼ 0.00 (0%)
FLYNG 7.34 Decreased By ▼ -0.13 (-1.74%)
GGGL 10.75 Increased By ▲ 0.30 (2.87%)
GGL 16.94 Increased By ▲ 0.55 (3.36%)
GTECH 8.30 Decreased By ▼ -0.07 (-0.84%)
HUMNL 6.45 No Change ▼ 0.00 (0%)
KEL 3.02 Increased By ▲ 0.09 (3.07%)
LOTCHEM 29.15 Increased By ▲ 0.81 (2.86%)
MLCF 28.30 Increased By ▲ 0.22 (0.78%)
OGDC 76.53 Increased By ▲ 2.68 (3.63%)
PAEL 15.87 Increased By ▲ 0.32 (2.06%)
PIBTL 5.43 Increased By ▲ 0.08 (1.5%)
PRL 17.69 Increased By ▲ 0.30 (1.73%)
SILK 1.08 Increased By ▲ 0.01 (0.93%)
TELE 10.82 Decreased By ▼ -0.14 (-1.28%)
TPL 8.60 Increased By ▲ 0.79 (10.12%)
TPLP 21.19 Increased By ▲ 1.53 (7.78%)
TREET 23.80 Decreased By ▼ -0.05 (-0.21%)
TRG 127.50 Increased By ▲ 0.60 (0.47%)
UNITY 23.10 Increased By ▲ 0.04 (0.17%)
WAVES 11.63 Increased By ▲ 0.08 (0.69%)
WTL 1.14 No Change ▼ 0.00 (0%)
BR100 4,174 Increased By 48.3 (1.17%)
BR30 15,806 Increased By 310.9 (2.01%)
KSE100 41,518 Increased By 366.7 (0.89%)
KSE30 15,562 Increased By 142.1 (0.92%)
World

US FDA approves J&J's multiple sclerosis treatment

  • The FDA approved Ponvory as a daily oral drug to treat relapsing forms of multiple sclerosis, a debilitating neurological condition in which the immune system eats away at the protective covering of nerves.
Published March 19, 2021
Follow us

The US Food and Drug Administration has approved Johnson & Johnson's multiple sclerosis (MS) treatment, Ponvory, the company's unit Janssen Pharmaceutical Co said on Friday.

The FDA approved Ponvory as a daily oral drug to treat relapsing forms of multiple sclerosis, a debilitating neurological condition in which the immune system eats away at the protective covering of nerves.

The approval was based on data from a two-year late-stage study where Ponvory demonstrated superior efficacy in significantly reducing annual relapses by about 30% compared to Sanofi's approved MS drug Aubagio, the company said.

Comments

Comments are closed.